# AstraZeneca PLC (AZN) stock: price and valuation

URL: https://funkfolio.com/stock/AZN

> AstraZeneca PLC (AZN) trades at $182.27, is worth $282.69B, is priced at 25.8× earnings and scores 72/100. Valuation, financials and signals.

---

## AstraZeneca PLC (AZN)

AstraZeneca PLC (AZN) is a healthcare company (drug manufacturers - general) based in the United Kingdom. The share price is $182.27, down 0.95% on the day, which values the company at $282.69B. Price as of 17 Nov 2026, 22:06 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $182.27 −0.95% today
- **Market value:** $282.69B
- **P/E ratio:** 25.8× last 12 months
- **Forward P/E:** 16.1×
- **Dividend yield:** 1.76%
- **Funk Score:** 72/100
- **Against its own history:** About its usual price usual price $174.37
- **200-week average:** $153.93 18% above

Figures as of 17 Nov 2026, 22:06 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### AstraZeneca PLC in more detail

AZN trades at 25.8× its last twelve months' earnings, 16.1× next year's expected earnings, 4.5× sales. Measured against its own history, the price is 5% above what its usual multiples would imply ($174.37) — about its usual price. It sits 18% above its 200-week average of $153.93.

Its Funk Score is 72 out of 100 (financial strength 6.2, profitability 8.0, growth 7.8, value 6.6, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

12 of the superinvestors tracked here hold AZN, including Sarah Ketterer (20.2% of the portfolio), Primecap team (1.8% of the portfolio), Lew Sanders (1.1% of the portfolio).

### Superinvestors holding AZN

12 of the investors tracked here report a position in their latest 13F filing.

- [Sarah Ketterer Causeway Capital Management](https://funkfolio.com/gurus/sarah-ketterer) 20.2% of portfolio · $1.8B · added · Q3 2026
- [Primecap team Primecap Management](https://funkfolio.com/gurus/primecap) 1.81% of portfolio · $2.9B · added · Q3 2026
- [Lew Sanders Sanders Capital](https://funkfolio.com/gurus/lew-sanders) 1.09% of portfolio · $1.1B · added · Q3 2026
- [Brandon Haley Holocene Advisors](https://funkfolio.com/gurus/brandon-haley) 1.05% of portfolio · $460.7M · trimmed · Q2 2026
- [Larry Robbins Glenview Capital Management](https://funkfolio.com/gurus/larry-robbins) 0.70% of portfolio · $34.9M · new · Q2 2026
- [Ken Fisher Fisher Investments](https://funkfolio.com/gurus/ken-fisher) 0.53% of portfolio · $1.9B · added · Q3 2026
- [Temasek Temasek Holdings](https://funkfolio.com/gurus/temasek) 0.44% of portfolio · $160.3M · added · Q3 2026
- [Andrew Spokes Farallon Capital Management](https://funkfolio.com/gurus/farallon) 0.37% of portfolio · $71M · trimmed · Q3 2026
- [Steve Cohen Point72 Asset Management](https://funkfolio.com/gurus/steve-cohen) 0.21% of portfolio · $134.9M · trimmed · Q2 2026
- [Polen Capital team Polen Capital Management](https://funkfolio.com/gurus/polen-capital) 0.02% of portfolio · $2.2M · trimmed · Q3 2026
- [Dodge & Cox team Dodge & Cox](https://funkfolio.com/gurus/dodge-and-cox) 0.01% of portfolio · $8.9M · trimmed · Q3 2026
- [Rajiv Jain GQG Partners](https://funkfolio.com/gurus/rajiv-jain) 0.00% of portfolio · $1.1M · trimmed · Q3 2026

### Health Care companies of similar size

- [Eli Lilly LLY](https://funkfolio.com/stock/LLY)
- [Johnson & Johnson JNJ](https://funkfolio.com/stock/JNJ)
- [AbbVie ABBV](https://funkfolio.com/stock/ABBV)
- [Merck & Co MRK](https://funkfolio.com/stock/MRK)
- [UnitedHealth Group UNH](https://funkfolio.com/stock/UNH)
- [Novartis NVS](https://funkfolio.com/stock/NVS)
- [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO)
- [Amgen AMGN](https://funkfolio.com/stock/AMGN)
- [Gilead Sciences GILD](https://funkfolio.com/stock/GILD)
- [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT)
- [Novo Nordisk NVO](https://funkfolio.com/stock/NVO)
- [Pfizer PFE](https://funkfolio.com/stock/PFE)

Side by side: [AZN vs NVS (AstraZeneca PLC vs Novartis)](https://funkfolio.com/compare/azn-vs-nvs) [AZN vs UNH (AstraZeneca PLC vs UnitedHealth Group)](https://funkfolio.com/compare/azn-vs-unh) [AZN vs TMO (AstraZeneca PLC vs Thermo Fisher Scientific)](https://funkfolio.com/compare/azn-vs-tmo) [AZN vs MRK (AstraZeneca PLC vs Merck & Co)](https://funkfolio.com/compare/azn-vs-mrk) [AZN vs AMGN (AstraZeneca PLC vs Amgen)](https://funkfolio.com/compare/amgn-vs-azn)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United Kingdom](https://funkfolio.com/companies/country/united-kingdom) [All stocks A–Z](https://funkfolio.com/stocks)

### AstraZeneca PLC (AZN): questions and answers

**What is AZN's P/E ratio?**

AstraZeneca PLC trades at 25.8× its last twelve months' earnings and 16.1× next year's expected earnings. At its fiscal year-ends over the past 4 years the P/E ranged from 28.1× to 64.3×, with a median of 32.2×.

**What is AZN's PEG ratio?**

AstraZeneca PLC's PEG ratio is 1.33 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is AstraZeneca PLC's market cap?**

AstraZeneca PLC is valued at $282.69B at a share price of $182.27.

**Is AZN overvalued or undervalued?**

Against its own history, AZN is about its usual price: the price is 5% above the $174.37 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is AZN above its 200-week moving average?**

Yes. AZN is 18.4% above its 200-week average of $153.93. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is AstraZeneca PLC growing?**

Over the last three fiscal years AstraZeneca PLC's revenue grew 9.8% a year and its earnings per share 45.8% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “AstraZeneca PLC (AZN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/AZN

Underlying data: Yahoo Finance; company filings with the SEC.
